These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 16672644)

  • 1. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.
    Maier M; Seabrook TJ; Lazo ND; Jiang L; Das P; Janus C; Lemere CA
    J Neurosci; 2006 May; 26(18):4717-28. PubMed ID: 16672644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
    Lemere CA
    Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice.
    Liu B; Frost JL; Sun J; Fu H; Grimes S; Blackburn P; Lemere CA
    J Neurosci; 2013 Apr; 33(16):7027-37. PubMed ID: 23595760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting".
    Leverone JF; Spooner ET; Lehman HK; Clements JD; Lemere CA
    Vaccine; 2003 May; 21(17-18):2197-206. PubMed ID: 12706711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Abeta immunogens: is shorter better?
    Lemere CA; Maier M; Peng Y; Jiang L; Seabrook TJ
    Curr Alzheimer Res; 2007 Sep; 4(4):427-36. PubMed ID: 17908047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice.
    Seabrook TJ; Thomas K; Jiang L; Bloom J; Spooner E; Maier M; Bitan G; Lemere CA
    Neurobiol Aging; 2007 Jun; 28(6):813-23. PubMed ID: 16725229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G).
    Maier M; Seabrook TJ; Lemere CA
    Vaccine; 2005 Oct; 23(44):5149-59. PubMed ID: 16054274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants.
    Lemere CA; Spooner ET; Leverone JF; Mori C; Clements JD
    Neurobiol Aging; 2002; 23(6):991-1000. PubMed ID: 12470794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.
    Kim HD; Jin JJ; Maxwell JA; Fukuchi K
    Immunol Lett; 2007 Sep; 112(1):30-8. PubMed ID: 17686533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response.
    Zou J; Yao Z; Zhang G; Wang H; Xu J; Yew DT; Forster EL
    J Neurol Sci; 2008 Sep; 272(1-2):87-98. PubMed ID: 18571202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short amyloid-β immunogens with spacer-enhanced immunogenicity without junctional epitopes for Alzheimer's disease immunotherapy.
    Guan X; Zou J; Gu H; Yao Z
    Neuroreport; 2012 Oct; 23(15):879-84. PubMed ID: 22922658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapeutic efficiency of a tetravalent Aβ1-15 vaccine in APP/PS1 transgenic mice as mouse model for Alzheimer's disease.
    Guan X; Yang J; Gu H; Zou J; Yao Z
    Hum Vaccin Immunother; 2013 Aug; 9(8):1643-53. PubMed ID: 23732905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.
    Sigurdsson EM; Knudsen E; Asuni A; Fitzer-Attas C; Sage D; Quartermain D; Goni F; Frangione B; Wisniewski T
    J Neurosci; 2004 Jul; 24(28):6277-82. PubMed ID: 15254082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
    Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
    ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation.
    Obregon D; Hou H; Bai Y; Nikolic WV; Mori T; Luo D; Zeng J; Ehrhart J; Fernandez F; Morgan D; Giunta B; Town T; Tan J
    Neurobiol Dis; 2008 Feb; 29(2):336-53. PubMed ID: 18055209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol.
    Spooner ET; Desai RV; Mori C; Leverone JF; Lemere CA
    Vaccine; 2002 Dec; 21(3-4):290-7. PubMed ID: 12450704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease.
    Kim HD; Tahara K; Maxwell JA; Lalonde R; Fukuiwa T; Fujihashi K; Van Kampen KR; Kong FK; Tang DC; Fukuchi K
    J Gene Med; 2007 Feb; 9(2):88-98. PubMed ID: 17219449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine efficacy of transcutaneous immunization with amyloid β using a dissolving microneedle array in a mouse model of Alzheimer's disease.
    Matsuo K; Okamoto H; Kawai Y; Quan YS; Kamiyama F; Hirobe S; Okada N; Nakagawa S
    J Neuroimmunol; 2014 Jan; 266(1-2):1-11. PubMed ID: 24315156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial.
    Davtyan H; Ghochikyan A; Petrushina I; Hovakimyan A; Davtyan A; Poghosyan A; Marleau AM; Movsesyan N; Kiyatkin A; Rasool S; Larsen AK; Madsen PJ; Wegener KM; Ditlevsen DK; Cribbs DH; Pedersen LO; Agadjanyan MG
    J Neurosci; 2013 Mar; 33(11):4923-34. PubMed ID: 23486963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.
    Town T; Tan J; Sansone N; Obregon D; Klein T; Mullan M
    Neurosci Lett; 2001 Jul; 307(2):101-4. PubMed ID: 11427310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.